title: PARP inhibitors in BRCA mutation-associated ovarian cancer.
authors.affiliation: Institute of Cancer Sciences, The Christie and University of Manchester, Withington, Manchester M20 4BX, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Clamp
authors.affiliation: Institute of Cancer Sciences, The Christie and University of Manchester, Withington, Manchester M20 4BX, UK. Electronic address: gordon.jayson@manchester.ac.uk.
authors.forename: Gordon
authors.initials: G
authors.lastname: Jayson
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010793:Phthalazines / Q000008:administration & dosage*; D010879:Piperazines / Q000008:administration & dosage*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C531550:olaparib